Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

Cab033 says, "...I agree that the last dilution was orcastrated by dans personal agenda."

That's nonsense. You guys talking about Dan's personal agenda have no understanding of the financing process and requirements of pre-revenue biotechs. ADXS had the chance to raise money on favorable terms. That's to shareholder benefit without any question. That Dan was ready and able to do that deserves huge kudos from shareholders and pricing his options after the raise made totally good sense. Paying an executive well (giving him well-priced options) is to shareholders' benefit because it keeps him doing what he did: raising money on favorable terms.

Seriously, you don't understand business and you're only misleading others on this board who have a similar lack of experience/ expertise. Sorry to be so harsh, but I posted a fairly long piece analytical about Dan's comp that I thought clarified and settled this issue.

Can we please stay focused on information and analysis that is actually relevant to the future of this company?